Other Meetings

Other Meetings

On-site reporting from other meetings and summits in the hematology/oncology arena

On location

In Chronic Myeloid Leukemia, Subsidies and Out-of-Pocket Costs Predict Adherence to Tyrosine Kinase Inhibitors

CHICAGO--An analysis of Surveillance, Epidemiology, and End Results (SEER) and Medicare Part D data suggests that coverage barriers are not the only factors that...
On location

Minimal Residual Disease Status Linked to Survival Outcomes in Multiple Myeloma

Although many patients with multiple myeloma (MM) achieve a complete response (CR) with treatment, the likelihood of relapse is still high, suggesting the presence...
On location

In the Era of Novel Agents, Has Early Mortality in Older Patients Decreased?

While novel agents for the treatment of multiple myeloma (MM) have improved patient outcomes and extended survival, these agents are also associated with toxicities...
On location

Novel Agent Marizomib Demonstrates Promising Activity in Relapsed/Refractory Multiple Myeloma

Marizomib (NPI-0052), a novel proteasome inhibitor, decreased the amount of myeloma protein and was well tolerated in patients with relapsed/refractory multiple myeloma (MM), according...
On location

Pooled Analysis Shows Maintenance Therapy Improves Survival in Multiple Myeloma

Though previous studies have indicated prolonged progression-free survival (PFS) with maintenance therapy in patients with multiple myeloma (MM), experts disagree about its effect on...
On location

Autologous Transplant Improves Complete Response, Disease Control in Patients Treated with Carfilzomib-Based Combo

In a phase I/II trial of patients with newly diagnosed multiple myeloma (MM), 55 percent of patients treated with the combination of carfilzomib, lenalidomide,...
On location

Results from a Phase II Study of Crenolanib in Patients With FLT3-Positive Acute Myeloid...

CHICAGO--The next-generation tyrosine kinase inhibitor (TKI) crenolanib besylate showed “encouraging” activity and safety as a single agent in patients with relapsed/refractory FLT3-positive acute myeloid...
On location

CLL-IPI: A New and Improved Staging System for CLL?

In a recent study examining the validity of prognostic markers for patients with chronic lymphocytic leukemia (CLL), researchers believe they have developed an internationally...
On location

Study Finds Idarucizumab Can Reverse the Anticoagulant Effects of Dabigatran

The experimental drug idarucizumab quickly and effectively reversed the anticoagulant effect of dabigatran within minutes, according to results from an interim analysis presented at...

Pacritinib Leads to Better Symptom Control, Improved Cytopenias in Myelofibrosis

Compared with other available treatments, the JAK2 inhibitor pacritinib leads to more effective spleen volume reduction and better symptom control in patients with myelofibrosis,...

Current Issue

Mid-January 2021 Annual Meeting Edition

This issue features highlights from the 2020 ASH Annual Meeting, a look at doctor-patient gifting customs around the world, and more.

Block title